Syneron Medical — Merger or Acquisition (September 2009)
15 slides from Syneron Medical's merger presentation, Sep 29, 2009
Slide 1: Creating a Leading Global Aesthetic Device Company / Safe Harbor
Exhibit 99.1 CREATING A LEADING GLOBAL AESTHETIC DEVICE COMPANY September 2009 SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS Statements in this document regarding the proposed transaction between Candela Corporation and Syneron Medical Ltd., including, without limitation, the expected timetable for com
Slide 2: Regulation FD / Today's Presenters
In addition, the statements in this document reflect the expectations and beliefs of Candela Corporation and/or Syneron Medical Ltd. as of the date of this document. Candela Corporation and Syneron Medical Ltd. anticipate that subsequent events and developments will cause their expectations and beli
Slide 3: Investment Highlights
Gerard Puorro Chief Executive Officer of Candela Fabian Tenenbaum Chief Financial Officer of Syneron 3 INVESTMENT HIGHLIGHTS Combination of Syneron and Candela creates a leading global aesthetic device company Comprehensive product portfolio Syneron’s proprietary elôs (electrical-optical synergy) te
Slide 4: Transaction Overview / Attractive Market Opportunity
4 TRANSACTION OVERVIEW Candela shareholders will receive 0.2911 ordinary shares of Syneron for each share of Candela common stock Syneron to issue 6.7 million shares Represents $2.84 per share considerations—51% premium to prior close(1) Total consideration of approximately $65 million(1) Fixed Exch
Slide 5: Application Size and Growth Areas
4.0 under pressure from insurance Safer and easier-to-use technology opens up market to emerging medical specialties and 2.0 non-medical professionals (OUS) 1.1 100% private pay 0.0 1997 2003 2006 2007 2008 _____________ Source: American Society for Aesthetic Plastic Surgery (ASAPS) 2008 Insight / W
Slide 6: New Products To Address Growth Markets
Body Contouring Fractional Skin Treatment Cellulite Reduction Ablative Non-Ablative Laser-Assisted Lipolysis Wrinkle Reduction Hair Removal Skin Rejuvenation Leg Veins / Vascular Skin Tightening Tattoo / Pigment Removal Acne Treatment Best-In-Class Products 8 New Products To Address Growth Markets B
Slide 7: Sublative Rejuvenation System
9 Growth Opportunity: Skin Rejuvenation / Fractional Rejuvenation 3.6 Million Procedures in the U.S. in 2008 (CAGR 08-13: 15.8%) Faster growing than BOTOX Cosmetic Procedures are up for people with ethnic skin – up 18% in Hispanic population alone Rapidly growing demand by Asian market 2 major innov
Slide 8: Growth Opportunity: Cellulite Reduction/Body Shaping
Low Epidermal Disruption with High Dermal Remodeling - little to no downtime Multi-Treatment approach creates bundling opportunity Proprietary single use disposable tip 11 Growth Opportunity: Cellulite Reduction/Body Shaping Liposuction still among top five surgical cosmetic procedures in 2008: ASAP
Slide 9: Growth Opportunity: Hair Removal
VelaShape – Clear leader in non-invasive body shaping Over 3 Million procedures performed to date Installed base of 6500 units worldwide FDA Clearance for circumferential reduction VelaShape consumer brand recognition 40,000 hits per month on VelaShape website Only manufacturer that produces viable
Slide 10: Best in Class Product Portfolio – Gentle Family of Lasers
14 Best in Class Product Portfolio – Gentle Family of Lasers Integrated treatment workstation Multi-laser capability Treats all skin types Treatment versatility Best in class hair removal to skin tightening to pigmented lesions to vascular Unmatched results No compromises in technology, speed or eff
Slide 11: Alex TriVantage / Global Distribution Footprint
volume: CAGR 08-13 12.8%3 35% of Tattoo removal consumers seek an additional service from the provider4 Courtesy: Christine C. Dierickx, MD Skin and Laser Center, Antwerp, Belgium 1 Northwestern University Study, JAAD, June 2006 2 Recurring mistakes in tattoo removal, Dermatology, DOI: 10.1159/00018
Slide 12: Balanced Penetration of Key Customer Segments
Candela Syneron Combined 31% 40% 46% 52% 57% + = 69% 60% 54% 48% 43% 2007 2009 2007 1H 2009 Pro Forma Fiscal Year June Fiscal Year December International North America 18 BALANCED PENETRATION OF KEY CUSTOMER SEGMENTS Segment #Worldwide Combined Medical Professionals “Core” (Dermatologists 50,000 20%
Slide 13: Well Positioned for Growth / Financial Strength
Source: Addressable market based on management assessment * US market data only 19 WELL POSITIONED FOR GROWTH 6 major platform launches in last 18 months in growth segments Body shaping product line extensions Sublative Rejuvenation™ Fractional ablative resurfacing Multi-color tattoo removal Hair re
Slide 14: Summary
$240 million cash, no debt Recent dramatic operating expense reductions given macroeconomic conditions Recurring revenue from service and consumables Profitable business and accretive transaction post-integration as environment normalizes *Based on US publicly traded companies only; For example, the
Slide 15: yneron’ CANDELA
S yneron’ CANDELA
Syneron Medical — Merger or Acquisition (September 2009) on 6ix